NEU 1.03% $19.30 neuren pharmaceuticals limited

ROW Rights, page-160

  1. 519 Posts.
    lightbulb Created with Sketch. 1225
    now we have the confirmation that Acadia with its 4 million shares given by neuren as part of the agreement in August is the maker of downward manipulation on the market. the goal was clearly to depress the capitalization of Neuren to make the mediocre offer for rights appear more than it is. now by logic, the market must restore value to this company that proves to be decisive and convinced to be worth much more. I also note that for the first time the management opens to a total sale of the company.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.